{"id":"utidelone-plus-intermittent-capecitabine","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"15-25%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-15%","effect":"Vomiting"},{"rate":"5-10%","effect":"Anemia"},{"rate":"5-10%","effect":"Thrombocytopenia"},{"rate":"5-10%","effect":"Neutropenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting Plk1, Utidelone disrupts the cell cycle, leading to cell death in cancer cells. This mechanism is particularly effective in cancers with high Plk1 expression, such as certain types of leukemia and lymphoma. The addition of intermittent Capecitabine, a chemotherapy agent, further enhances the anti-tumor effects of Utidelone.","oneSentence":"Utidelone is a novel, orally administered, small molecule inhibitor of the polo-like kinase 1 (Plk1), which plays a critical role in cell cycle progression and is overexpressed in various cancers.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:54:44.043Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia (AML)"},{"name":"Diffuse large B-cell lymphoma (DLBCL)"}]},"trialDetails":[{"nctId":"NCT05172518","phase":"PHASE3","title":"Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-03-01","conditions":"Breast Neoplasms, Locally Advanced or Metastatic Breast Cancer","enrollment":512}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Utidelone plus Intermittent Capecitabine","genericName":"Utidelone plus Intermittent Capecitabine","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Utidelone is a novel, orally administered, small molecule inhibitor of the polo-like kinase 1 (Plk1), which plays a critical role in cell cycle progression and is overexpressed in various cancers. Used for Acute myeloid leukemia (AML), Diffuse large B-cell lymphoma (DLBCL).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}